Melatonin

Melatonin has been studied in 923 papers since 1986: 213 trials and 58 observational studies in people, 315 in animals, 30 in cells, 286 reviews; 154 in the past year. It is an approved medicine. The newest paper, Nov 11, 2026: “Constructing functionalized cartilage organoids by preserving mitochondrial homeostasis to accelerate cartilage repair”.

InterventionApproved 2007

923 papers study it171 more mention it1,236 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 9% slower than aging research as a whole: 44 papers in the latest year counted

Part of Rhonda Patrick's supplement routineMore supplements

32 new papers in 30 daysSee all 882 papers on melatonin

At a glance

Melatonin extends lifespan and reduces oxidative stress in mice in reports from independent labs, which also report improved human sleep. A mouse result shows no clear lifespan effect, and some human trials show no clear sleep benefit. Human observational data link melatonin with higher heart failure hospitalization; some papers report company ties, and companies sponsor trials across its uses.

1,236 findings in 507 papers from 1986 to 2026, 38 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 265 independent labs in 45 countries; 210 trials, 3 about aging, 57 with no results posted.

“sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).”
The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled TrialCritical care medicine2020doi:10.1097/ccm.0000000000004690

88 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 265 independent labs in 45 countries
  • 88 findings against
  • 210 trials, 3 about aging, 57 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 11 of 1,125 findings with company ties
  • 10 of 210 trials sponsored by its developers
  • Human trial112
  • Humans51
  • Animals285
  • Model organisms6
  • Cells26
  • In silico3

91 studies gave melatonin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases ghrelin4.35 ± 0.90 pg/mL vs. 4.78 ± 0.75 pg/mL; p = 0.013

no change: Has no effect on 2-arachidonoylglycerol

no change: Has no effect on hedonic appetite intensity

Randomized trial8 weeks41 peopleWomen35.68 ± 7.51 yearsOverweight or obesity and high hedonic appetiteScientific reports, Oct 18, 2026

down: Decreases low-density lipoprotein cholesterol

down: Decreases triglyceride

Randomized trial12 weeks38 peopleWomenPostmenopausal womenExperimental gerontology, Oct 10, 2026

up: Increases bone mineral density

up: Improves quality of life

Randomized trial6 months60 peopleWomen≥45 yearsMidlife adults; Older adults; Postmenopausal women; with calcium and vitamin D supplementationInternational Journal of Drug Delivery Technology, Jun 29, 2026

up: Improves leg muscle strength

up: Improves unipedal static balance

Randomized trial12 weeks36 peoplePost-interventionInternational journal of food sciences and nutrition, Jun 24, 2026

down: Decreases sleep disturbances-3.6 ± 1.6 vs. -1.4 ± 0.5

Randomized trialeight weeks200 peopleBothaged 18 to 50 yearsAdults aged 18 to 50 years who met the DSM-5 diagnostic criteria for sleep disturbanceClocks & sleep, Mar 27, 2026

What did lifespan studies of melatonin find?

DrugAge

DrugAge records 12 results from 5 papers: 5 in mice, 4 in P. tetraurelia and 3 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of melatonin find?

448

Studies of melatonin measured 448 outcomes; the most studied are oxidative stress and ROS signaling (30 studies), cellular senescence (27) and inflammation (23).

Oxidative stress and ROS signaling

downin rats10downin reviews7downin humans5downin mice4+4

30 studies
  1. Melatonin decreases oxidative stress and ROS signaling in humans (diabetic hemodialysis patients) (β = -0.21 μmol/L, 95% CI -0.36 to -0.06).

    “plasma malondialdehyde (β = -0.21 μmol/L, 95% CI -0.36 to -0.06, P = .005)”

    Human trialdiabetic hemodialysis patients2 x 5mg/day12 weeksn = 60

    The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  2. Melatonin decreases oxidative stress and ROS signaling in humans under methadone maintenance treatment (β -0.31, 95% CI -0.57 to -0.05).

    “malondialdehyde (β -0.31; 95% CI, -0.57, -0.05; P = 0.02) and protein carbonyl (β -0.06; 95% CI, -0.09, -0.04; P < 0.001)”

    Human trialunder methadone maintenance treatmentcapsules10 mg12 weeksn = 54

    The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment

    Addiction biology

  3. Melatonin decreases oxidative stress and ROS signaling.

    “Melatonin complements these actions through mitochondrial redox protection, preservation of bioenergetics, and circadian regulation.”

    Review

    Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction

    Preprints.orgPreprint

  4. Melatonin decreases oxidative stress and ROS signaling in rats (LPS-induced).

    “attenuating LPS-induced oxidative stress and inflammatory damage in placental tissue and trophoblast cells.”

    AnimalsLPS-inducedplacentafemales

    Combined treatment with metformin and melatonin improves placental mitochondrial function via the AMPK/SIRT3 pathway in an LPS-induced model of preeclampsia

    European journal of pharmacology

  5. Melatonin decreases oxidative stress and ROS signaling in mice.

    “The administration of the antioxidant melatonin to 16-month-old mice significantly ameliorated oxidative stress”

    Animalsgastrointestinal tract

    Early melatonin partially delays gut aging in mice

    Biochimica et biophysica acta. Molecular basis of disease

  6. Melatonin decreases oxidative stress and ROS signaling in experimental studies of age-related vascular diseases.

    “Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”

    Reviewin experimental studies of age-related vascular diseases

    Melatonin for age-related vascular diseases: mechanistic rationale, translational barriers, and clinical prospects

    Molecular biology reports

  7. Melatonin protects against oxidative stress and ROS signaling in humans.

    “Furthermore, melatonin promotes amyloid clearance via the glymphatic and lymphatic systems, protects neurons from oxidative damage, and reduces Tau hyperphosphorylation.”

    Review

    Physiological Implications of Pancreatic Amyloid Polypeptide Aggregation and Its Inhibition by Melatonin

    International journal of molecular sciences

  8. Melatonin decreases oxidative stress and ROS signaling in aged IR-injured rats.

    “MLT treatment significantly alleviated liver injury, reducing oxidative stress and inflammatory markers expression.”

    Animalsin aged IR-injured ratsliver1 mg/100 g body weightmales

    Protective effect of melatonin against age-related ischemia-reperfusion injury is associated with the NLRP3 inflammasome pathway

    Journal of physiology and biochemistry

  9. Melatonin decreases oxidative stress and ROS signaling in malnourished young male rats.

    “Both MLT administration and TE reduced these adverse effects, improving behavioral performance, slowing CSD, and attenuating prooxidant markers.”

    Animalsin malnourished young male ratssubcutaneouscortex10 mg/kg on alternate daysP25 to P55males

    Physical exercise/melatonin interaction in young rats fed a low-protein diet: a behavioral, electrophysiological, and redox balance analysis

    Frontiers in aging neuroscience

  10. Melatonin decreases oxidative stress and ROS signaling in humans (WMD: -1.54 μmol/L, 95% CI: -2.07, -1.01).

    “malondialdehyde (WMD: -1.54 μmol/L, 95% CI: -2.07, -1.01)”

    Review

    Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis

    Nutrients

All 30

More on Oxidative stress and ROS signaling

Cellular senescence

downin mice9downin reviews6downin human cells5downin cells3+3

27 studies
  1. Melatonin decreases cellular senescence in STZ-induced diabetic mice and high-glucose-stimulated HK-2 cells.

    “melatonin effectively reduced the levels of cellular senescence marker proteins (p53, p21, p16INK4A, and γ-H2AX), decreased the SA-β-gal positive staining area”

    Animalsin STZ-induced diabetic mice and high-glucose-stimulated HK-2 cellskidney

    Melatonin suppresses cellular senescence in diabetic kidney disease though the Wnt/β-catenin signaling pathway

    European journal of pharmacology

  2. Melatonin decreases cellular senescence in plaques and in hydrogen peroxide-stimulated VSMCs; suppression abolished by luzindole.

    “Melatonin markedly suppressed VSMC senescence in both plaques and hydrogen peroxide-stimulated VSMCs”

    Animalsin plaques and in hydrogen peroxide-stimulated VSMCs; suppression abolished by luzindolevascular smooth muscle cells

    Melatonin attenuates atherosclerotic plaque vulnerability through SIRT6-dependent regulation of vascular smooth muscle cells senescence

    Redox biology

  3. Melatonin decreases cellular senescence.

    “melatonin can alleviate DPSCs senescence by inhibiting the expression of matrix metalloproteinase”

    Reviewdental pulp stem cell

    Senescence of dental pulp stem cells: phenotypes, underlying mechanisms and regulatory molecules

    Human cell

  4. Melatonin decreases cellular senescence in bone marrow mesenchymal stem cell senescence.

    “We assess current interventions aimed at reducing BMSC senescence, with an emphasis on pharmacological methods like melatonin and antioxidants, alongside nonpharmacological strategies, such as exercise and dietary supplementation with omega-3 fatty acids.”

    Reviewin bone marrow mesenchymal stem cell senescence

    Bone Marrow Mesenchymal Stem Cell Senescence in the Development of Osteoporosis: Mechanisms, Interventions, and Future Directions

    Current molecular medicine

  5. Melatonin decreases cellular senescence in cells.

    “melatonin inhibited macrophage senescence and improved chemotherapy responsiveness”

    Cellsmacrophages

    Melatonin-mediated cGAS-STING signal in senescent macrophages promote TNBC chemotherapy resistance and drive the SASP

    The Journal of biological chemistry

  6. Melatonin decreases cellular senescence in acute skeletal muscle injury model.

    “Melatonin treatment was found to attenuate the injury-induced senescence of FAPs.”

    Animalsin acute skeletal muscle injury model100 μM in vitro, 20 mg/kg/day in vivo5 days in vitro, 15 days in vivo

    The role of oxidative stress-mediated fibro-adipogenic progenitor senescence in skeletal muscle regeneration and repair

    Stem cell research & therapy

  7. Melatonin decreases cellular senescence in senescent pituitary cells.

    “melatonin reduced the levels of senescence-related markers in senescent pituitary cells”

    Cellsin senescent pituitary cellspituitary

    Neuregulin 1 mitigated prolactin deficiency through enhancing TRPM8 signaling under the influence of melatonin in senescent pituitary lactotrophs

    International journal of biological macromolecules

  8. Melatonin decreases cellular senescence.

    “Melatonin has been shown to reduce senescence and promote autophagy within disc cells, vital for clearing out damaged cellular components”

    Reviewintervertebral disc

    Melatonin: Evolving Physiological Understanding and Potential Therapeutic Role in Pain Medicine Including Intervertebral Disc Degeneration

    Pain physician

  9. Melatonin decreases cellular senescence in mice after optic nerve crush.

    “Melatonin also suppressed ONC-induced senescence and apoptosis index.”

    Animalsafter optic nerve crushretina

    Melatonin ameliorates retinal ganglion cell senescence and apoptosis in a SIRT1-dependent manner in an optic nerve injury model

    Biochimica et biophysica acta. Molecular basis of disease

  10. Melatonin decreases cellular senescence in high glucose conditions.

    “In vitro, melatonin inhibited STAT3 phosphorylation and lowered cellular senescence and apoptosis markers, in a manner similar to the STAT3 inhibitor S3I-201.”

    Cellsin high glucose conditions

    Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation

    Life sciences

All 28

More on Cellular senescence

Inflammation

downin rats7downin reviews7downin mice5downin humans4

23 studies
  1. Melatonin decreases inflammation in humans under methadone maintenance treatment (β -0.15, 95% CI -0.27 to -0.02).

    “melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (β -0.15; 95% CI, -0.27, -0.02; P = 0.02)”

    Human trialunder methadone maintenance treatmentcapsules10 mg12 weeksn = 54

    The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment

    Addiction biology

  2. Melatonin decreases inflammation in experimental studies of age-related vascular diseases.

    “Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”

    Reviewin experimental studies of age-related vascular diseases

    Melatonin for age-related vascular diseases: mechanistic rationale, translational barriers, and clinical prospects

    Molecular biology reports

  3. Melatonin decreases inflammation in humans (WMD: -0.59 mg/L, 95% CI: -0.94, -0.23).

    “C-reactive protein (WMD: -0.59 mg/L, 95% CI: -0.94, -0.23)”

    Review

    Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis

    Nutrients

  4. Melatonin decreases inflammation in rats.

    “melatonin attenuated the expression of pro-inflammatory markers”

    Animalsintraperitoneally10 mg/kg30 daysmales

    Melatonin Reduced Hyperexcitability and Enhanced Sleep Oscillations in the Hippocampus and Prefrontal Cortex of Aged Male Rats

    Neurochemical research

  5. Melatonin inhibits inflammation (Alzheimer's disease pathology).

    “regulating amyloid beta (Aβ)-induced neuroinflammation”

    ReviewAlzheimer's disease pathology

    Melatonin Supplementation in Alzheimer's disease: The Potential Role in Neurogenesis

    Molecular neurobiology

  6. Melatonin decreases inflammation.

    “melatonin's promising antioxidant, anti-inflammatory, and immunomodulatory properties”

    Review

    Melatonin supplementation: new insights into health and disease

    Sleep & breathing = Schlaf & Atmung

  7. Melatonin decreases inflammation in mice (aged mice on high-fat diet).

    “It also suppressed inflammatory markers (e.g., TNF-α, NLRP3, NF-κB, IL-1β, and CEBPB)”

    Animalsaged mice on high-fat dietepididymal white adipose tissue

    Protective Effects of Exogenous Melatonin Administration on White Fat Metabolism Disruption Induced by Aging and a High-Fat Diet in Mice

    Antioxidants (Basel, Switzerland)

  8. Melatonin decreases inflammation in intermittent hypoxia-exposed mice.

    “melatonin treatment reduced the levels of the proinflammatory cytokines, interleukin-1β, interleukin-6, and tumor necrosis factor-α”

    Animalsin intermittent hypoxia-exposed mice

    Melatonin attenuates intermittent hypoxia-induced cognitive impairment in aged mice: The role of inflammation and synaptic plasticity

    Psychoneuroendocrinology

  9. Melatonin decreases inflammation (Alzheimer's disease).

    “melatonin exerts a significant role in AD prevention and treatment via its antioxidant effects, reducing neuroinflammation, and Aβ.”

    ReviewAlzheimer's disease

    Harnessing the benefits of physical exercise-induced melatonin: a potential promising approach to combat Alzheimer's disease by targeting beta-amyloid (Aβ)

    Hormones (Athens, Greece)

  10. Melatonin decreases inflammation in patients with diabetes (SMD = -0.75, 95% CI: -1.37, -0.12).

    “melatonin can lead to significant reductions in levels of C-reactive protein (CRP) [SMD = -0.75; 95% CI: -1.37, -0.12; P = 0.018]”

    Reviewin patients with diabetesn = 823

    Effects of melatonin supplementation on markers of inflammation and oxidative stress in patients with diabetes: A systematic review and meta-analysis of randomized controlled trials

    Clinical nutrition ESPEN

All 23

More on Inflammation

Apoptosis

downin mice7downin rats3downin human cells1downin humans1+3

14 studies
  1. Melatonin decreases apoptosis in experimental studies of age-related vascular diseases.

    “Experimental studies consistently indicate that melatonin can reduce oxidative stress, inflammatory signaling, apoptosis, mitochondrial dysfunction, vascular smooth muscle cell phenotypic switching, and endothelial impairment.”

    Reviewin experimental studies of age-related vascular diseases

    Melatonin for age-related vascular diseases: mechanistic rationale, translational barriers, and clinical prospects

    Molecular biology reports

  2. Melatonin decreases apoptosis in humans.

    “Anti-oxidants such as coenzyme Q10, melatonin, and nicotinamide have been shown to mitigate oxidative stress, enhance mitochondrial function, reduce apoptosis, and im-prove the quality of oocytes”

    Review

    Female reproductive capacity preservation: antioxidant strategies in combating ovarian aging and cryopreservation challenges

    Frontiers in endocrinology

  3. Melatonin decreases apoptosis in granulosa cells.

    “promote autophagy and reduce apoptosis of GCs”

    Cellsin granulosa cellsgranulosa cell

    Exogenous melatonin alleviates premature ovarian failure by regulating granulosa cell autophagy

    NPJ Regenerative medicine

  4. Melatonin decreases apoptosis in mice after optic nerve crush.

    “Melatonin also suppressed ONC-induced senescence and apoptosis index.”

    Animalsafter optic nerve crushretina

    Melatonin ameliorates retinal ganglion cell senescence and apoptosis in a SIRT1-dependent manner in an optic nerve injury model

    Biochimica et biophysica acta. Molecular basis of disease

  5. Melatonin induces apoptosis in mouse cells.

    “Melatonin promoted apoptosis of RAW264.7 cells”

    CellsRAW264.7

    Melatonin induces RAW264.7 cell apoptosis via the BMAL1/ROS/MAPK-p38 pathway to improve postmenopausal osteoporosis

    Bone & joint research

  6. Melatonin decreases apoptosis in high glucose conditions.

    “In vitro, melatonin inhibited STAT3 phosphorylation and lowered cellular senescence and apoptosis markers, in a manner similar to the STAT3 inhibitor S3I-201.”

    Cellsin high glucose conditions

    Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation

    Life sciences

  7. Melatonin decreases apoptosis in kidneys of DN mice.

    “Melatonin treatment decreased the positive area of senescence-associated galactosidase (SA-β-gal) staining and the number of TUNEL-positive cells in kidneys of DN mice.”

    Animalsin kidneys of DN micekidney

    Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation

    Life sciences

  8. Melatonin decreases apoptosis in mice (cardiac aging).

    “melatonin recovered mitochondrial architecture, reduced apoptosis and multivesicular bodies' formation”

    Animalscardiac agingcardiomyocyte

    The Impact of Melatonin Supplementation and NLRP3 Inflammasome Deletion on Age-Accompanied Cardiac Damage

    Antioxidants (Basel, Switzerland)

  9. Melatonin decreases apoptosis in mice (aged heart).

    “Melatonin supplementation also had an anti-apoptotic action”

    Animalsaged heartheart

    Melatonin/Nrf2/NLRP3 Connection in Mouse Heart Mitochondria during Aging

    Antioxidants (Basel, Switzerland)

  10. Melatonin decreases apoptosis in rats (propofol-treated).

    “decreased the apoptotic cell counts in the regions of HIP and PFC.”

    Animalspropofol-treatedhippocampus and prefrontal cortex

    Prophylactic Melatonin Treatment Ameliorated Propofol-Induced Cognitive Dysfunction in Aged Rats

    Neurotoxicity research

All 15

More on Apoptosis

Sleep quality

upin humans7no changein humans3

10 studies
  1. Melatonin improves sleep quality in humans.

    “Results of the analysis of percentage difference between pre‐ and post‐intervention for the above‐mentioned factors, plus menopausal status, after adjusting for age, showed an isolated effect of group (p < 0.001) and shift (p = 0.023), but not menopausal status (p = 0.86), on sleep quality on days off (Table of Supporting Information”

    Human trial3 monthsfemalesn = 46

    Low-Dose Melatonin, Climacteric Symptoms and Sleep in Female Shift Workers: A Randomized Controlled Trial

    Journal of pineal research

  2. Melatonin improves sleep quality in humans (on days off) (+35.33% (p < 0.001)).

    “Sleep quality improved by 35.33% on days off in the intervention group (p < 0.001)”

    Human trialon days off0.3 mgfemalesn = 46

    Low-Dose Melatonin, Climacteric Symptoms and Sleep in Female Shift Workers: A Randomized Controlled Trial

    Journal of pineal research

  3. Melatonin improves sleep quality in humans (hospitalized patients; before-and-after comparison).

    “Results showed significant improvement after melatonin across all measures, with increased sleep duration, faster sleep onset, fewer awakenings, and better reported sleep quality.”

    Human trialhospitalized patients; before-and-after comparison

    Improving Sleep Quality and Quantity in Hospitalized Patients With Melatonin: A Quality Improvement Project at HCA (Hospital Corporation of America) Oak Hill Hospital

    Cureus

  4. Melatonin showed no clear effect on sleep quality in humans (advanced primary open-angle glaucoma).

    “No significant differences were found between melatonin and placebo for any sleep or quality of life outcomes.”

    Human trialadvanced primary open-angle glaucomaoral5 mg30 daysn = 64

    Effects of Melatonin Supplementation on Sleep Quality in Patients with Advanced Glaucoma: A Randomized, Double-Masked, Placebo-Controlled Crossover Trial

    Ophthalmology. Glaucoma

  5. Melatonin improves sleep quality in humans (p < 0.001).

    “Melatonin administration, however, caused a significant improvement in sleep quality which was significantly impaired in NS versus NNS at baseline (p < 0.001).”

    Human trialsustained-release2 mg12 weeksn = 24

    Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study

    Pharmacological research

  6. Melatonin showed no clear effect on sleep quality in humans (postoperative orthopedic trauma patients) (PSQI 5.6 vs 6.1, P = 0.615).

    “melatonin PSQI = 5.6, placebo PSQI = 6.1, P = 0.615”

    Human trialpostoperative orthopedic trauma patients5 mg4 weeks

    Effectiveness of melatonin treatment for sleep disturbance in orthopaedic trauma patients: A prospective, randomized control trial

    Injury

  7. Melatonin improves sleep quality in humans (critically ill ICU patients) (69.7 vs 60.7, p = 0.029).

    “sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).”

    Human trialcritically ill ICU patientsoral10 mgup to seven consecutive nightsn = 203

    The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial

    Critical care medicine

  8. Melatonin improves sleep quality in humans (chronic kidney disease) (WMD = -3.75, 95% CI: -6.92, -0.57).

    “improved sleep quality (PSQI: WMD = -3.75, 95% CI: -6.92, -0.57, p = 0.021”

    Reviewchronic kidney disease

    The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis

    Frontiers in nutrition

  9. Melatonin improves sleep quality in humans.

    “improving sleep quality and addressing specific neurodegenerative diseases”

    Review

    Melatonin supplementation: new insights into health and disease

    Sleep & breathing = Schlaf & Atmung

  10. Melatonin improves sleep quality in COVID-19 patients.

    “improving the quality of sleep, which could also help COVID-19 patients achieve better clinical outcomes.”

    Reviewin COVID-19 patients

    Sleep, Dietary Melatonin Supplementation, and COVID-19

    Current medicinal chemistry

All 11

SIRT1

upin rats6upin mice1upin rat cells1upin reviews1

9 studies
  1. Melatonin increases SIRT1 in mice after optic nerve crush.

    “melatonin partially rescued the expression of SIRT1 in RGC 3 days after ONC”

    Animalsafter optic nerve crushretinal ganglion cells3 days after optic nerve crush

    Melatonin ameliorates retinal ganglion cell senescence and apoptosis in a SIRT1-dependent manner in an optic nerve injury model

    Biochimica et biophysica acta. Molecular basis of disease

  2. Melatonin increases SIRT1 in diabetic elderly female rat model.

    “the highest retinal SIRT1 expression values were obtained in the diabetes + melatonin (G4) group.”

    Animalsin diabetic elderly female rat modelretinal tissue4 weeksfemalesn = 24

    Melatonin protects retinal tissue damage in streptozotocin-induced aged rats

    Archives of gerontology and geriatrics

  3. Melatonin increases SIRT1 in streptozotocin-induced diabetic aged female rats.

    “suppressed antioxidant activity and decreased GLUT4, SIRT1, and PGC-1α gene expression in heart tissue can be reversed by the combination of resveratrol, melatonin, and resveratrol + melatonin”

    Animalsin streptozotocin-induced diabetic aged female ratsresveratrol, melatonin, and resveratrol + melatoninheart5 mg/kg/day4 weeksfemalesn = 48

    The effects of resveratrol and melatonin on biochemical and molecular parameters in diabetic old female rat hearts

    Experimental gerontology

  4. Melatonin activates SIRT1 in rat cells (ovariectomy-derived BMMSCs).

    “Melatonin reversed the differentiation switch of OVX-BMMSCs from osteogenesis to adipogenesis by activating the SIRT1 signaling pathway.”

    Cellsovariectomy-derived BMMSCs

    Melatonin suppresses bone marrow adiposity in ovariectomized rats by rescuing the imbalance between osteogenesis and adipogenesis through SIRT1 activation

    Journal of orthopaedic translation

  5. Melatonin increases SIRT1 in rats (non-exercised ovariectomized rats).

    “Melatonin treatment or its co-administration with HRT upregulated the expressions of IL-10 and SIRT1”

    Animalsnon-exercised ovariectomized ratsheart and thoracic aorta4 mg/kg/dayfemales

    Melatonin Alleviates Ovariectomy-Induced Cardiovascular Inflammation in Sedentary or Exercised Rats by Upregulating SIRT1

    Inflammation

  6. Melatonin increases SIRT1 in ovariectomized non-exercised rats.

    “Melatonin treatment or its co-administration with HRT upregulated the expressions of IL-10 and SIRT1”

    Animalsin ovariectomized non-exercised ratsoralheart and thoracic aorta4 mg/kg/day10 weeksfemales

    Melatonin Alleviates Cardiovascular Inflammation in Sedentary or Exercised Postmenopausal Rats by Upregulating SIRT1

    Research SquarePreprint

  7. Melatonin increases SIRT1 in ALAN-exposed rats.

    “while upregulating the aging (Sirt 1) gene expression in both young and old melatonin supplemented ALAN exposed groups.”

    Animalsin ALAN-exposed ratsoralbrain10 mg Kg−110 daysmales

    Age-dependent effect of continuous 'artificial light at night' on circadian rhythm in male rats: neuroprotective role of melatonin

    Biogerontology

  8. Melatonin increases SIRT1.

    “Furthermore, melatonin upregulates SIRT-1, which reduces NF-κB activity by de-acetylation of NF-κB subunits.”

    Review

    Control of Mesenchymal Stromal Cell Senescence by Tryptophan Metabolites

    International journal of molecular sciences

  9. Melatonin increases SIRT1 in rats (melatonin from 24 h before MCA occlusion (PrevT)).

    “while hippocampal levels of sirtuin 1 (SIRT1) and B-cell lymphoma 2 (Bcl-2) increased”

    Animalsmelatonin from 24 h before MCA occlusion (PrevT)hippocampus24 h before surgery to 7 days after

    Comparison of the Effect of Melatonin Treatment before and after Brain Ischemic Injury in the Inflammatory and Apoptotic Response in Aged Rats

    International journal of molecular sciences

More on SIRT1

Cognitive function

upin mice2upin rats2no changein humans1downin humans1+2

7 studies
  1. Melatonin showed no clear effect on cognitive function in humans (Mild Cognitive Impairment).

    “Accordingly, there were no significant differences between melatonin and placebo interventions in any of the secondary outcomes.”

    Human trialMild Cognitive Impairmentoral25 mg12 weeksn = 40

    3-Month Melatonin Supplementation to Reduce Brain Oxidative Stress and Improve Sleep in Mild Cognitive Impairment: A Randomised Controlled Feasibility Trial

    Journal of pineal research

  2. Melatonin improves cognitive function in intermittent hypoxia-exposed mice.

    “melatonin attenuated IH-induced impairment of learning and memory in aged mice”

    Animalsin intermittent hypoxia-exposed mice

    Melatonin attenuates intermittent hypoxia-induced cognitive impairment in aged mice: The role of inflammation and synaptic plasticity

    Psychoneuroendocrinology

  3. Melatonin improves cognitive function in doxorubicin-treated rats.

    “Mel and Met equally improved those brain pathologies, resulting in cognitive improvement in DOX-treated rats.”

    Animalsin doxorubicin-treated rats10 mg/kg/day30 consecutive daysmalesn = 8

    Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain

    Neurotoxicology

  4. Melatonin showed no clear effect on cognitive function in ovariectomized rats.

    “Heart rates and memory performances of the postmenopausal rats were not changed significantly by none of the applications.”

    Animalsin ovariectomized rats10 weeksfemales

    Melatonin Alleviates Cardiovascular Inflammation in Sedentary or Exercised Postmenopausal Rats by Upregulating SIRT1

    Research SquarePreprint

  5. Melatonin impairs cognitive function in humans (healthy-subjects).

    “In healthy-subjects, although daytime melatonin treatment notably decreased in accuracy by correct responses [SMD: -0.74 (-1.03; -0.45) p < 0.00001]”

    Reviewhealthy-subjectsdaytime

    Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials

    Neuroscience and biobehavioral reviews

  6. Melatonin improves cognitive function in humans (mild stage of AD).

    “melatonin significantly improved MMSE score in mild stage of AD [MD: 1.89 (0.96; 2.82) p < 0.0001].”

    Reviewmild stage of AD

    Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer's disease and insomnia: A systematic review and meta-analysis of randomized controlled trials

    Neuroscience and biobehavioral reviews

  7. Melatonin improves cognitive function in aged rats fed a high-fat diet.

    “MLT reversed HFD-induced cognitive decline as measured by a water maze test”

    Animalsin aged rats fed a high-fat diet

    Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high-fat diet

    Journal of pineal research

  8. Melatonin improves cognitive function in 3xTg-AD mice.

    “melatonin reversed cognitive impairment and dementia-associated behaviors of anxiety and apathy”

    Animalsin 3xTg-AD mice10 mg/kg daily6 to 12 months of age

    Melatonin induces mechanisms of brain resilience against neurodegeneration

    Journal of pineal research

Quality of life

upin humans5no changein humans1

6 studies
  1. Melatonin improves quality of life in humans with calcium and vitamin D supplementation.

    “the physical domain showed significant improvement in the melatonin group (p=0.042)”

    Human trialwith calcium and vitamin D supplementation3 mg daily6 monthsfemales

    Effect of Melatonin on bone health and quality of life In Postmenopausal women

    International Journal of Drug Delivery Technology

  2. Melatonin improves quality of life in humans (breast cancer patients receiving antihormone medications).

    “The quality of life and sexual function were enhanced by a four-week melatonin treatment.”

    Human trialbreast cancer patients receiving antihormone medications3 mg twice a dayfour weeksn = 60

    Exploring the Efficacy of Melatonin in Alleviating Menopausal Symptoms in Breast Cancer Survivors: A Randomized, Double-Blind, Placebo-Controlled Study

    Advanced biomedical research

  3. Melatonin improves quality of life in humans during pulmonary rehabilitation in patients with COPD (-6.9 ± 3.0 vs. -1.9 ± 2.4, p < 0.01).

    “and quality of life (-6.9 ± 3.0 vs. -1.9 ± 2.4; p < 0.01), compared to the placebo group.”

    Human trialduring pulmonary rehabilitation in patients with COPD3 mg/day12 weeksn = 39

    Melatonin supplementation enhances pulmonary rehabilitation outcomes in COPD: a randomized, double-blind, placebo-controlled study

    Respiratory medicine

  4. Melatonin improves quality of life in hemodialysis patients.

    “EX-MEL induced better results in some domains of QoL compared with EX-PLA.”

    Human trialin hemodialysis patients12 weeksn = 33

    Effects of intradialytic exercise in combination with melatonin supplementation on functional capacity, postural balance, and quality of life in hemodialysis patients

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

  5. Melatonin showed no clear effect on quality of life in humans (postoperative orthopedic trauma patients).

    “Melatonin treatment did not significantly improve subjective sleep quality, pain, quality of life or opioid use.”

    Human trialpostoperative orthopedic trauma patients5 mg4 weeks

    Effectiveness of melatonin treatment for sleep disturbance in orthopaedic trauma patients: A prospective, randomized control trial

    Injury

  6. Melatonin improves quality of life in humans (P = 0.002).

    “scores of HDRS, HARS, and total QLI in the melatonintreated group (P ≤0.001, 0.001, and 0.002, respectively).”

    Human trialtablets3 mg3 monthsn = 60

    Study of Exogenous Melatonin as a Treatment Modality for Sleep and Psychiatric Disorders in Hemodialysis Patients

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Malondialdehyde

downin humans2downin mice2downin rats2

6 studies
  1. Melatonin decreases malondialdehyde in humans (adjusted for baseline measures) (P<0.001).

    “After treatment, considerable differences were only seen between the two groups in serum MDA (P<0.001) and LDL-C (P=0.007) concentrations, adjusted for baseline measures.”

    Human trialadjusted for baseline measures6 mg/day12 weeks

    Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial

    Clinical rheumatology

  2. Melatonin decreases malondialdehyde in humans (chronic kidney disease) (-1.28 μmol/L, 95% CI: -2.50, -0.06).

    “reduced malondialdehyde (MDA: -1.28 μmol/L, 95% CI: -2.50, -0.06, p = 0.039”

    Reviewchronic kidney disease

    The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis

    Frontiers in nutrition

  3. Melatonin decreases malondialdehyde in cuprizone-treated young and aging mice.

    “Introducing melatonin to mice of any age reduced the number of GFAP+-, CD3+- cells and their subpopulations, macrophage activation, and MDA content.”

    Animalsin cuprizone-treated young and aging miceintraperitoneal injectionbrain1 mg/kg

    Reaction of different cell types of the brain on neurotoxin cuprizone and hormone melatonin treatment in young and aging mice

    Frontiers in cellular neuroscience

  4. Melatonin decreases malondialdehyde in diabetic elderly female rat model.

    “Again in our study, the highest retinal MDA values were obtained in the diabetes group (G3).”

    Animalsin diabetic elderly female rat modelretinal tissue4 weeksfemalesn = 24

    Melatonin protects retinal tissue damage in streptozotocin-induced aged rats

    Archives of gerontology and geriatrics

  5. Melatonin decreases malondialdehyde in rats (ovariectomized rats; administration at 9 am compared with 9 pm).

    “lower values of Type I collagen cross-linked C-telopeptide, procollagen type 1 N propeptide, and malondialdehyde (p = 0.013)”

    Animalsovariectomized rats; administration at 9 am compared with 9 pm30 mg/kg/day12 weeksn = 10

    Systemic administration with melatonin in the daytime has a better effect on promoting osseointegration of titanium rods in ovariectomized rats

    Bone & joint research

  6. Melatonin decreases malondialdehyde in mice.

    “The increases in TAOC and SOD level and decreases in MDA were detected in ovaries and uterus from melatonin-treated mice compared to the controls.”

    Animalsovary and uteruslong-termfemales

    Melatonin regulates the activities of ovary and delays the fertility decline in female animals via MT1/AMPK pathway

    Journal of pineal research

More on Malondialdehyde

TNF-alpha

downin humans2downin rats2no changein humans1downin M. unguiculatus1

6 studies
  1. Melatonin decreases TNF-alpha in women with polycystic ovary syndrome (P < 0.05).

    “Serum levels of tumor necrosis factor-α (TNF-α) declined significantly in the melatonin and co-supplementation groups compared to baseline (P < 0.05).”

    Human trialin women with polycystic ovary syndrome8 weeksfemalesn = 84

    Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial

    Biological trace element research

  2. Melatonin decreases TNF-alpha in ageing Mongolian gerbils.

    “reduced the levels of circulating tumor necrosis factor-α (TNF-α), immune globulin G (IgG) and corticosterone (CORT).”

    Animalsin ageing Mongolian gerbils

    Melatonin reduced colon inflammation but had no effect on energy metabolism in ageing Mongolian gerbils (Meriones unguiculatus)

    Comparative biochemistry and physiology. Toxicology & pharmacology : CBP

  3. Melatonin decreases TNF-alpha in humans (WMD = - 2.24 pg/ml; 95% CI - 3.45, - 1.03; P < 0.001).

    “Melatonin supplementation significantly decreased TNF-α and IL-6 levels [(WMD = - 2.24 pg/ml; 95% CI - 3.45, - 1.03; P < 0.001”

    Review

    Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials

    European journal of nutrition

  4. Melatonin decreases TNF-alpha in HFD-fed rats.

    “hippocampal levels of TNF-α in HFD-fed rats were reduced by MLT treatment”

    Animalsin HFD-fed ratshippocampus

    Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high-fat diet

    Journal of pineal research

  5. Melatonin decreases TNF-alpha in rats (melatonin from 24 h before MCA occlusion (PrevT)).

    “experienced a significant decrease in the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β)”

    Animalsmelatonin from 24 h before MCA occlusion (PrevT)cortex and hippocampus24 h before surgery to 7 days after

    Comparison of the Effect of Melatonin Treatment before and after Brain Ischemic Injury in the Inflammatory and Apoptotic Response in Aged Rats

    International journal of molecular sciences

  6. Melatonin showed no clear effect on TNF-alpha in humans (patients with metabolic syndrome and related disorders) (SMD = -1.87, 95% CI -3.81, 0.07).

    “however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = - 1.87; 95% CI - 3.81, 0.07; P = 0.05; I2: 94.4).”

    Reviewpatients with metabolic syndrome and related disorders

    The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials

    Inflammopharmacology

More on TNF-alpha

Body weight

downin humans2no changein humans1downin rats1upin rats1

5 studies
  1. Melatonin decreases body weight in humans.

    “According to our findings, weight and BMI reduced significantly at 12th week in the both groups.”

    Human trial12 weeksn = 44

    Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial

    BioMed research international

  2. Melatonin decreases body weight in humans (along with a weight-loss diet) (p = 0.01).

    “for the last six weeks, significant reductions of these parameters were observed only in the melatonin group (p = 0.01).”

    Human trialalong with a weight-loss diet3-milligram per day12 weeks

    Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial

    BioMed research international

  3. Melatonin showed no clear effect on body weight in humans.

    “However, no substantial effects were observed on BW, BMI, WC, and SBP compared to the control group.”

    Reviewn = 1,543

    Effect of melatonin supplementation on body composition and blood pressure in adults: A systematic review and Dose-Response meta-analysis of randomized controlled trial

    Heliyon

  4. Melatonin decreases body weight in rats (ovariectomized).

    “supplemented with low, medium, and high doses of Mel for 8 weeks exhibited reduced BW gain, perirenal fat mass, and gonads fat mass”

    Animalsovariectomized8 weeksfemales

    Effects of Melatonin Supplementation on Lipid Metabolism and Body Fat Accumulation in Ovariectomized Rats

    Nutrients

  5. Melatonin decreases body weight in humans (SMD -0.48, 95% CI -0.94 to -0.02, P < 0.01).

    “melatonin supplementation significantly reduced body weight (standardized mean difference, -0.48; 95% confidence interval, -0.94 to -0.02; P = <0.01; I2 = 92%).”

    Review

    Melatonin supplementation and anthropometric indicators of obesity: A systematic review and meta-analysis

    Nutrition (Burbank, Los Angeles County, Calif.)

  6. Melatonin increases body weight in rats with BDL-induced biliary cirrhosis.

    “There was an increase in weight gain and phase angle in the groups treated with MLT with/or EX comparing to the BDL group.”

    Animalsin rats with BDL-induced biliary cirrhosismales

    Sarcopenia, oxidative stress and inflammatory process in muscle of cirrhotic rats - Action of melatonin and physical exercise

    Experimental and molecular pathology

HOMA-IR

downin humans3no changein humans1downin reviews1

5 studies
  1. Melatonin showed no clear effect on HOMA-IR in humans.

    “There were no intergroup differences in CAVI, mtDNA, HOMA-IR, or SBP from the baseline to week six between the placebo and melatonin groups.”

    Human trialsix weeksfemalesn = 38

    Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study

    International journal of environmental research and public health

  2. Melatonin decreases HOMA-IR in patients with Parkinson's disease (β -0.47, 95% CI -0.80 to -0.13).

    “Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR)”

    Human trialin patients with Parkinson's disease10 mg/day12 weeksn = 60

    Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial

    Clinical neurology and neurosurgery

  3. Melatonin decreases HOMA-IR in humans (polycystic ovary syndrome) (β -0.28; 95% CI, -0.50, -0.05).

    “melatonin administration, compared with the placebo, significantly reduced serum insulin (β -1.20 μIU/mL; 95% CI, -2.14, -0.26; P = 0.01), homeostasis model of assessment-insulin resistance (HOMA-IR)”

    Human trialpolycystic ovary syndromecapsules10 mg12 weeksfemalesn = 58

    Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

    Journal of affective disorders

  4. Melatonin decreases HOMA-IR (28 out of 33 studies).

    “melatonin supplementation reduced fasting plasma glucose (FPG, 14 out of 29 studies), fasting insulin (22 out of 28 studies), HOMA-IR (28 out of 33 studies), and increased QUICKI”

    Review10 mg

    Exploring effects of melatonin supplementation on insulin resistance: An updated systematic review of animal and human studies

    Diabetes & metabolic syndrome

  5. Melatonin decreases HOMA-IR in humans.

    “melatonin administration significantly reduced insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR)”

    Review

    Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

More on HOMA-IR

Mortality

downin A. cerana1no changein humans1upin humans1downin humans1HR 2.09

4 studies
  1. Melatonin showed no clear effect on mortality in humans (medically hospitalised older patients) (3.64% vs 1.85%, p=1.000).

    “28-day mortality (3.64% vs 1.85%, p=1.000)”

    Human trialmedically hospitalised older patients5 mg or 8 mgup to 5 daysn = 109

    Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE)

    BMJ open

  2. Melatonin is linked with higher mortality in humans (HR 2.09 (95% CI 1.99–2.18)).

    “All-cause mortality was higher in melatonin users (5, 118 [7.8%] vs 2, 820 [4.3%]; HR 2.09, 95% CI 1.99–2.18).”

    Humans5 years

    Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia

    AHA Scientific Sessions 2025 abstract

  3. Melatonin decreases mortality in A. cerana (at 37 °C).

    “most pronounced effect at 37 °C, where mortality was significantly reduced.”

    Model organismsat 37 °C20 μg/mL

    Melatonin Enhances Thermal Resilience and Extends Worker Lifespan in Apis cerana via Redox-Metabolic Reprogramming

    Insects

  4. Melatonin decreases mortality in patients admitted to intensive care units.

    “melatonin decreases the risks of severe complications, such as thrombosis and sepsis, and mortality rates.”

    Reviewin patients admitted to intensive care units

    Sleep, Dietary Melatonin Supplementation, and COVID-19

    Current medicinal chemistry

Fasting blood glucose

downin humans4

4 studies
  1. Melatonin decreases fasting blood glucose in patients with diabetic nephropathy (β = -10.64 mg/dL; 95% CI: -20.37 to -0.90; P < .05).

    “Melatonin administration significantly reduced plasma fasting glucose (β = -10.64 mg/dL; 95% CI: -20.37 to -0.90; P < .05)”

    Human trialin patients with diabetic nephropathyplasma10 mg/d12 weeksn = 60

    Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy

    Iranian journal of kidney diseases

  2. Melatonin decreases fasting blood glucose in humans (supplementation in adults) (WMD = -2.66 mg/dl, 95%CI: -4.53 to -0.80).

    “melatonin supplementation significantly reduced fasting blood sugar (WMD = -2.66 mg/dl, 95%CI: -4.53 to -0.80, n = 27)”

    Reviewsupplementation in adults

    Effects of melatonin supplementation on blood glycemic indices in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials

    Nutrition & metabolism

  3. Melatonin decreases fasting blood glucose in humans (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10).

    “fasting blood glucose (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10)”

    Review

    Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis

    Nutrients

  4. Melatonin decreases fasting blood glucose in diabetes (mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01).

    “Our meta-analysis showed significant results for fasting blood glucose [mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01; I2 = 58%]”

    Reviewin diabetes

    Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials

    Clinical nutrition (Edinburgh, Scotland)

More on Fasting blood glucose

C-reactive protein

downin humans3no changein humans1

4 studies
  1. Melatonin showed no clear effect on C-reactive protein in humans (diabetic nephropathy) (P = 0.81).

    “We did not observe any significant change in C-reactive protein (CRP) concentrations after melatonin intake (P = 0.81).”

    Human trialdiabetic nephropathy10 mg/day24 weeksn = 32

    The effects of melatonin administration on carotid intima-media thickness and pulse wave velocity in diabetic nephropathy: A randomized, double-blind, placebo-controlled trial

    Clinical nutrition ESPEN

  2. Melatonin decreases C-reactive protein in patients with Parkinson's disease (β -0.94 mg/L, 95% CI -1.55 to -0.32).

    “melatonin supplementation resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β -0.94 mg/L; 95% CI, -1.55, -0.32; P = 0.003)”

    Human trialin patients with Parkinson's disease10 mg/day12 weeksn = 60

    Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial

    Clinical neurology and neurosurgery

  3. Melatonin decreases C-reactive protein in humans (diabetic hemodialysis patients) (β = -1.92 mg/L, 95% CI -3.02 to -0.83).

    “melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive protein (β = -1.92 mg/L, 95% CI -3.02 to -0.83, P = .001)”

    Human trialdiabetic hemodialysis patients2 x 5mg/day12 weeksn = 60

    The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  4. Melatonin decreases C-reactive protein in humans (patients with metabolic syndrome and related disorders) (SMD = -1.80, 95% CI -3.27, -0.32).

    “melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = - 1.80; 95% CI - 3.27, - 0.32; P = 0.01; I2: 95.2)”

    Reviewpatients with metabolic syndrome and related disorders

    The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials

    Inflammopharmacology

More on C-reactive protein

All 448

What is melatonin linked with?

48

Studies link melatonin with 48 measures, among them postoperative delirium, circadian clock and clinical pregnancy rate.

Postoperative delirium

downin humans2RR 0.72

2 studies
  1. Melatonin lowers the risk of postoperative delirium in humans (elderly surgical patients) (RR 0.72; 95% CI 0.56-0.92; p = 0.009).

    “Overall, postoperative delirium occurred in 188/895 patients (21.0%) receiving melatonergic agents and 254/893 patients (28.4%) in control groups, corresponding to a significant reduction in POD (RR 0.72; 95% CI 0.56-0.92; p = 0.009).”

    Reviewelderly surgical patients

    Melatonin or ramelteon for the prevention of postoperative delirium in elderly patients: A systematic review and meta-analysis of randomized clinical trials

    Journal of clinical anesthesia

  2. Melatonin lowers the risk of postoperative delirium in humans (elderly postoperative patients).

    “subgroup analysis showed that melatonin significantly reduced the occurrence of POD”

    Reviewelderly postoperative patients

    Prophylactic effect of exogenous melatonin and melatonin receptor agonists on postoperative delirium in elderly patients: a systemic review and meta-analysis of randomized controlled trials

    Aging clinical and experimental research

More on Postoperative delirium

Circadian clock

upin humans1mixedin reviews1

2 studies
  1. Melatonin is associated with circadian clock.

    “promising chronobiotics such as melatonin, resveratrol, and their analogs are analysed in terms of their alignment with geroprotector criteria”

    Review

    Chronobiotics as potential geroprotectors

    Advances in gerontology = Uspekhi gerontologii

  2. Melatonin is associated with circadian clock in humans.

    “In reviewing the literature, a clear circadian melatonin profile with a nocturnal peak at 3 am and lower daytime levels was observed in the healthy, elderly population.”

    Review

    Melatonin profile in healthy, elderly subjects - A systematic literature review

    Chronobiology international

More on Circadian clock

Clinical pregnancy rate

upin humans1

1 study
  1. Melatonin is associated with clinical pregnancy rate (patients aged ≥ 38 years) (46.0% vs. 20.3%).

    “For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”

    Humanspatients aged ≥ 38 yearsat least eight weeks

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

  2. Melatonin is associated with clinical pregnancy rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (46.0% vs. 20.3%).

    “increasing clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01)”

    HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

Ongoing pregnancy rate

upin humans1

1 study
  1. Melatonin is associated with ongoing pregnancy rate (patients aged ≥ 38 years) (36.5% vs. 15.3%).

    “For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”

    Humanspatients aged ≥ 38 yearsat least eight weeks

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

  2. Melatonin is associated with ongoing pregnancy rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (36.5% vs. 15.3%).

    “ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01)”

    HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

Live birth rate

upin humans1

1 study
  1. Melatonin is associated with live birth rate (patients aged ≥ 38 years) (33.3% vs. 15.3%).

    “For patients ≥ 38 years, melatonin significantly improved clinical pregnancy rates (46.0% vs. 20.3%, P < 0.01), ongoing pregnancy rates (36.5% vs. 15.3%, P < 0.01), and live birth rates (33.3% vs. 15.3%, P < 0.05).”

    Humanspatients aged ≥ 38 yearsat least eight weeks

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

  2. Melatonin is associated with live birth rate in humans (Undergoing IVF-frozen embryo transfer cycles; compared with control) (33.3% vs. 15.3%).

    “live birth rates (33.3% vs. 15.3%, P < 0.05)”

    HumansUndergoing IVF-frozen embryo transfer cycles; compared with control2 mg daily≥ 8 weeksfemales

    Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age

    Reproductive biology and endocrinology : RB&E

Arrhythmia

upin humans1

1 study
  1. Melatonin is linked with a higher risk of arrhythmia in humans (0.80% vs. 0.71%, sRR 1.14 [1.06-1.22]).

    “melatonin users had a significantly higher 5-year risk of arrythmia compared with controls (0.80% vs. 0.71%, sRR 1.14 [1.06-1.22])”

    Humans5-year

    Melatonin may be linked to slightly higher irregular heartbeat risk

    ESC Congress 2026 abstract

More on Arrhythmia

Obesity incidence

downin humans1HR 0.51

1 study
  1. Melatonin is associated with obesity incidence in humans (Q3 versus Q1 in the fully adjusted multivariable Cox model) (49% lower risk; HR 0.51, 95% CI 0.34-0.75).

    “participants in Q3 (20,894.5-26,276.5 ng/day) had a 49% lower risk of incident obesity (HR 0.51; 95% CI 0.34-0.75; p = 0.001).”

    HumansQ3 versus Q1 in the fully adjusted multivariable Cox modelDietary melatonin20,894.5-26,276.5 ng/day (Q3)Mean 4.4 yearsBoth; 65.8% womensn = 3,736

    Dietary melatonin and obesity incidence: a non-linear association in the Brazilian cohort (CUME+ Study)

    Nutrition, metabolism, and cardiovascular diseases : NMCD

More on Obesity incidence

Hypertension

downin humans1OR 0.45

1 study
  1. Melatonin is linked with a lower risk of hypertension in humans (one-sample Mendelian randomization) (OR = 0.45, P = 0.015).

    “suggested a protective effect of higher serum melatonin levels on hypertension risk (OR = 0.45, P = 0.015)”

    Humansone-sample Mendelian randomization

    Identification of novel loci regulating circulating melatonin and its causal relationship with hypertension

    Human genetics

More on Hypertension

Parkinson's disease

upin humans1HR 1.63

1 study
  1. Melatonin is associated with Parkinson's disease in humans (compared with benzodiazepines in patients with sleep disorders) (HR 1.63, 95% CI 1.51-1.76).

    “Parkinson's disease (HR 1.63, 95% CI 1.51-1.76; HR 1.44, 95% CI 1.33-1.57)”

    Humanscompared with benzodiazepines in patients with sleep disorders

    Comparative dementia and Parkinson's disease risk associated with melatonin, benzodiazepine, or zolpidem use in patients with sleep disorders: a retrospective cohort study

    Scientific reports

More on Parkinson's disease

Dementia

upin humans1HR 2.09

1 study
  1. Melatonin is associated with dementia in humans (compared with benzodiazepines in patients with sleep disorders) (HR 2.09, 95% CI 2.01-2.16).

    “Melatonin use was associated with higher observed risk of all-cause dementia compared with benzodiazepines (HR 2.09, 95% CI 2.01-2.16)”

    Humanscompared with benzodiazepines in patients with sleep disorders

    Comparative dementia and Parkinson's disease risk associated with melatonin, benzodiazepine, or zolpidem use in patients with sleep disorders: a retrospective cohort study

    Scientific reports

More on Dementia

Change in sit-to-stand repetitions

upin humans1

1 study
  1. Melatonin is associated with change in sit-to-stand repetitions in humans (OL/Melatonin group) (r = 0.958, p = 0.04).

    “and positively associated with melatonin levels in the OL/Melatonin group (r = 0.958, p = 0.04).”

    Human trialOL/Melatonin group12 monthsfemales

    Pilot Study Assessing the Efficacy of Melatonin and Osteogenic Loading on Bone Health in a Postmenopausal Population with Osteopenia: MelaOstrong Randomized Controlled Trial

    Journal of pineal research

Poor sleep

downin humans1RR 0.21

1 study
  1. Melatonin lowers the risk of poor sleep in humans (critically ill ICU patients) (RR 0.21, 95% CI 0.06-0.71).

    “whereas 3.1% and 14.6% had very poor sleep (risk ratio, 0.21; 95% CI, 0.06-0.71), respectively.”

    Human trialcritically ill ICU patientsoral10 mgup to seven consecutive nightsn = 203

    The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial

    Critical care medicine

All 48

What acts on melatonin?

19

Studies name 19 things that act on melatonin, among them resistance training, high-intensity interval training and Korean dance program.

Resistance training

upin humans2

2 studies
  1. Resistance training increases melatonin in humans.

    “the elastic band group exhibited a significant increase in melatonin levels”

    Human trialeight weeksfemales

    Effects of Exercise Modalities on Body Composition, Oxidative Stress Marker(Malondialdehyde, MDA), and Antioxidant Capacity(Superoxide Dismutase, SOD; Melatonin) in Elderly Women

    Korean Journal of Sports Science

  2. Resistance training increases melatonin in humans (elderly T2DM patients with sleep disturbances).

    “Melatonin increased only in the intervention group (P<0.05)”

    Human trialelderly T2DM patients with sleep disturbances12 weeksn = 180

    Effects of resistance exercise combined with metformin on glycemic stability and sleep quality in elderly patients with type 2 diabetes mellitus with sleep disorders

    Pakistan journal of pharmaceutical sciences

More on Resistance training

High-intensity interval training

upin humans1

1 study
  1. High-intensity interval training increases melatonin in humans.

    “serum levels of the melatonin hormone (11.2 ± 2.3, p < 0.001), TAC (48.7 ± 7.1, p < 0.002), COX (3.7 ± 0.75, p < 0.001), and a higher percentage of lymphocyte apoptosis (5.2 ± 0.31, p < 0.003) were significantly increased following HIIT interventions”

    Human trial12 weeksmalesn = 80

    Effects of High-Intensity Interval Training on Melatonin Function and Cellular Lymphocyte Apoptosis in Sedentary Middle-Aged Men

    Medicina (Kaunas, Lithuania)

  2. High-intensity interval training increases melatonin in humans (11.2 ± 2.3, p < 0.001).

    “Data analysis showed a significant increase in the expression levels of the melatonin hormone (11.2 ± 2.3, p < 0.001)”

    Human trial12 weeksmalesn = 80

    Effects of High-Intensity Interval Training on Melatonin Function and Cellular Lymphocyte Apoptosis in Sedentary Middle-Aged Men

    Medicina (Kaunas, Lithuania)

More on High-intensity interval training

Korean dance program

upin humans1

1 study
  1. Korean dance program increases melatonin in humans (pooled across six studies, older women) (effect size = .770, 95% CI .088–1.452 (moderate effect)).

    “moderate effects were observed for growth hormone (effect size = .577, 95% CI = .195~.960) and melatonin (effect size = .770, 95% CI = .088~1.452).”

    Human trialpooled across six studies, older womenfemales

    Meta-Analysis of the Effects of Participation in Korean Dance Program on Aging-Related Hormones in Elderly Women

    Journal of Sport and Dance Science

More on Korean dance program

Photobiomodulation

no changein humans1

1 study
  1. Photobiomodulation showed no clear effect on melatonin in humans (insomnia symptoms).

    “No significant changes were observed in actigraphy-derived sleep indicators or melatonin measures.”

    Human trialinsomnia symptomstwo weeksn = 59

    Effects of bright light and near-infrared light on insomnia symptoms in community-dwelling older adults: a randomized clinical trial

    Photodiagnosis and photodynamic therapy

More on Photobiomodulation

Institutionalization

upin humans1

1 study
  1. Institutionalization is linked with higher melatonin in humans (institutionalized individuals vs individuals living with family members).

    “Blood cortisol (p = 0.0309) and melatonin (p = 0.0407) were also elevated.”

    Humansinstitutionalized individuals vs individuals living with family members

    Hormonal and Cytokine Imbalances Promote a Proinflammatory Profile in Institutionalized Elderly

    Brain sciences

More on Institutionalization

Yoga

upin humans1

1 study
  1. Yoga increases melatonin in humans (pooled SMD 0.37 (95% CI 0.09 to 0.66)).

    “the role of yogic techniques on melatonin levels, with a pooled SMD of 0.37 (95% - CI: [0.09; 0.66])”

    Review

    Meta-analysis of the Effect of Yogic Techniques on Melatonin Levels: Implications for Sleep Health

    International journal of yoga

More on Yoga

Light at night

downin cynomolgus monkeys1

1 study
  1. Light at night decreases melatonin in cynomolgus monkeys.

    “intensity-dependently reduced melatonin secretion”

    Animals10 monthsn = 137

    Nocturnal Light Pollution Synergistically Impairs Glucose Metabolism With Age and Weight in Monkeys

    Journal of diabetes research

More on Light at night

Physical exercise

upin reviews1

1 study
  1. Physical exercise increases melatonin.

    “can also lead to an increase in melatonin levels.”

    Review

    Harnessing the benefits of physical exercise-induced melatonin: a potential promising approach to combat Alzheimer's disease by targeting beta-amyloid (Aβ)

    Hormones (Athens, Greece)

More on Physical exercise

SARS-COV-2 infection

upin humans1

1 study
  1. SARS-COV-2 infection is linked with higher melatonin in elderly patients.

    “There was an increase in IL-6, IL-17, and melatonin in the group of elderly individuals with infection.”

    Humansin elderly patients

    Melatonin and Cytokines Modulate Daily Instrumental Activities of Elderly People with SARS-CoV-2 Infection

    International journal of molecular sciences

More on SARS-COV-2 infection

Constant light

no changein rhesus monkeys1

1 study
  1. Constant light showed no clear effect on melatonin in rhesus monkeys.

    “There were no significant changes in melatonin secretion both in young and old animals.”

    Animals24 h light/day, 330-400 lux4 to 8 weeksfemales

    Age-related and individual features of the HPA axis stress responsiveness under constant light in nonhuman primates

    Frontiers in endocrinology

More on Constant light

Electromagnetic field shielding bed

upin humans1

1 study
  1. Electromagnetic field shielding bed increases melatonin in humans.

    “Hormones, serotonin (Fig. A, p < 0.001), oxytocin (Fig. B, p < 0.001) and melatonin (Fig. C, p < 0.05), increased significantly after sleeping for two months on HOGO bed.”

    Human trialtwo monthsn = 28

    Improvement of several stress response and sleep quality hormones in men and women after sleeping in a bed that protects against electromagnetic fields

    Environmental health : a global access science source

More on Electromagnetic field shielding bed

Blue-enriched polychromatic light

downin humans1

1 study
  1. Blue-enriched polychromatic light decreases melatonin in humans (young adults; compared with non-blue-enriched light).

    “In young individuals, light exposure at 6500 K significantly attenuated the increase in endogenous melatonin levels”

    Human trialyoung adults; compared with non-blue-enriched light6500 K~40 lx2 hn = 31

    Age-related neuroendocrine and alerting responses to light

    GeroScience

More on Blue-enriched polychromatic light

All 19

Has melatonin been tested in people?

3 of 210 about aging

Yes: 213 trials and 58 observational studies in people have been published, and 209 trials are registered.

Approved

  • EMA Circadin

    Jun 29, 2007Sleep Initiation and Maintenance Disorders, primary insomnia

  • EMA Slenyto

    Sep 20, 2018Sleep Initiation and Maintenance Disorders, insomnia

  • EMA Melatonin Neurim

    Nov 7, 2022Sleep Initiation and Maintenance Disorders, primary insomnia

Repurposing

40 of 126

Every condition in trials

  • Attention deficit disorder with hyperactivity

    Phase 4Status unknown4 trials

  • Dental anxiety

    Phase 4Completed1 trial

  • Health Condition 1: O- Medical and Surgical

    Phase 3Status unknown3 trials

  • Dyssomnias

    Phase 3Completed2 trials

  • IVF

    Phase 3Status unknown1 trial

  • Squamous cell carcinoma of head and neck

    Phase 3Results posted1 trial

All 16

Stopped

  • NCT01033565TerminatedSleep-wake disorder

    Unsuccessful in recruiting appropriate subjects.

  • NCT02654314TerminatedDelirium

    Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.

  • NCT02454855TerminatedTumor

    The study stopped for futility after the DSMB.

  • NCT01598259TerminatedBurns

    lack or enrollment, funding depletion

  • NCT02190838TerminatedMelanoma

    Preliminary terminated due to inefficacy

  • NCT03540485TerminatedMultiple sclerosis

    Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the study schedule.

All 8

Who is developing melatonin?

1 company: Neurim Pharmaceuticals.

Companies
  • Neurim PharmaceuticalsPhase 2primary insomnia

Trial sponsors

Funding

14 grants since 2016

Japan Society for the Promotion of Science¥55.6MGouvernement du Canada | Canadian Institutes of Health ResearchCA$44.5KNational Institute of Diabetes and Digestive and Kidney Diseases$117K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that melatonin extends mouse lifespan and improves human sleep quality, but some sleep studies and a mouse lifespan study show no clear benefit. Human observational work links melatonin with higher heart failure hospitalization risk. Across uses, some trials ended over a year ago without posted results; companies sponsor some trials, and some papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Melatonin extends mouse lifespan and improves human sleep quality in reports from independent labs, alongside reports of no clear effect on either outcome. Three registered trials concern aging; across all uses, 56 trials ended over a year ago without posted results or citing papers. Company ties are declared in five papers, and Neurim Pharmaceuticals sponsors seven trials.

  3. Summary rewritten as its findings changed.

    As it read before

    Melatonin extends mouse lifespan and reduces oxidative stress across independent labs, but other mouse results show no lifespan effect. Independent labs report improved human sleep quality, alongside trials reporting no benefit. Among assessed trial registrations, none are aging-related; 57 have no posted results or citing papers over a year after ending, and papers disclose company ties.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that melatonin extends mouse lifespan and improves human sleep; other reports find no effect on these outcomes, and a human study associates melatonin with heart failure hospitalization. None of the assessed trials are judged aging-related; 64 ended over a year ago without posted results or citing papers. An author is affiliated with Neurim Pharmaceuticals, which sponsors seven trials.

  5. Summary rewritten as its findings changed.

    As it read before

    Melatonin extends mouse lifespan across independent labs, although other mouse studies report no effect or shorter lifespan. One group reports a human association with higher heart failure risk; the National Natural Science Foundation of China is a named funder. No trials concern aging; across uses, 64 ended over a year ago without posted results or citing papers, and seven have Neurim Pharmaceuticals sponsorship.

Latest

Dec 2025: 16Jan 2026: 18Feb 2026: 24Mar 2026: 22Apr 2026: 13May 2026: 12Jun 2026: 16Jul 2026: 13Aug 2026: 10Sep 2026: 5Oct 2026: 20Nov 2026: 9178 papers in 12 months

See all 882 papers on melatonin